Bill Text: NY A01384 | 2017-2018 | General Assembly | Introduced

---

Bill Title: Adds cannabimimetic agents to the schedule of controlled substances.

Spectrum: Moderate Partisan Bill (Democrat 25-6)

Status: (Engrossed - Dead) 2018-01-23 - REFERRED TO CODES [A01384 Detail]

Download: New_York-2017-A01384-Introduced.html

---

                STATE OF NEW YORK
        ________________________________________________________________________
                                          1384
                               2017-2018 Regular Sessions
                   IN ASSEMBLY
                                    January 12, 2017
                                       ___________
        Introduced  by  M. of A. ZEBROWSKI, CUSICK, ORTIZ, GALEF, COLTON, JENNE,
          BRINDISI, JAFFEE, TITUS, GUNTHER, COOK, TITONE,  MAGNARELLI,  BARRETT,
          STIRPE, BUCHWALD, LOPEZ, MOSLEY, HUNTER -- Multi-Sponsored by -- M. of
          A.  BARCLAY, CROUCH, DINOWITZ, FINCH, HAWLEY, MAGEE, McKEVITT, MONTES-
          ANO,  PALMESANO,  PEOPLES-STOKES, PERRY, RODRIGUEZ, STECK -- read once
          and referred to the Committee on Health
        AN ACT to amend the public health law, in relation to adding  cannabimi-
          metic agents to the schedule of controlled substances
          The  People of the State of New York, represented in Senate and Assem-
        bly, do enact as follows:
     1    Section 1. Schedule I of section 3306 of  the  public  health  law  is
     2  amended by adding a new subdivision (g) to read as follows:
     3    (g)  (1) Cannabimimetic agents. Unless specifically exempted or unless
     4  listed in another schedule, any material, compound, mixture, or prepara-
     5  tion that is not approved by the federal food  and  drug  administration
     6  (FDA)  which  contains  any  quantity of cannabimimetic agents, or which
     7  contains their salts, isomers, and salts of isomers whenever the  exist-
     8  ence of such salts, isomers, and salts of isomers is possible within the
     9  specific chemical designation.
    10    (2)  As  used  in  this  subdivision, the term "cannabimimetic agents"
    11  means any substance that is a cannabinoid receptor type 1 (CB1 receptor)
    12  agonist as demonstrated by binding studies and functional assays  within
    13  any of the following structural classes:
    14    (i)  2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position
    15  of the phenolic ring by alkyl or alkenyl, whether or not substituted  on
    16  the cyclohexyl ring to any extent.
    17    (ii)  3-(1-naphthoyl)indole  or 3-(1-naphthylmethane)indole by substi-
    18  tution at the nitrogen atom of the indole ring, whether or  not  further
    19  substituted on the indole ring to any extent, whether or not substituted
    20  on the naphthoyl or naphthyl ring to any extent.
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD04439-01-7
        A. 1384                             2
     1    (iii)  3-(1-naphthoyl)pyrrole  by substitution at the nitrogen atom of
     2  the pyrrole ring, whether or not further substituted in the pyrrole ring
     3  to any extent, whether or not substituted on the naphthoyl ring  to  any
     4  extent.
     5    (iv)  1-(1-naphthylmethylene)indene  by substitution of the 3-position
     6  of the indene ring, whether or not further  substituted  in  the  indene
     7  ring  to  any extent, whether or not substituted on the naphthyl ring to
     8  any extent.
     9    (v) 3-phenylacetylindole or 3-benzoylindole  by  substitution  at  the
    10  nitrogen  atom of the indole ring, whether or not further substituted in
    11  the indole ring to any extent, whether or not substituted on the  phenyl
    12  ring to any extent.
    13    (3) Such term includes:
    14    (i)      5-(1,1-dimethylheptyl)-2-{(1R,3S)-3-hydroxycyclohexyl}-phenol
    15  (CP-47,497);
    16    (ii)      5-(1,1-dimethyloctyl)-2-{(1R,3S)-3-hydroxycyclohexyl}-phenol
    17  (cannabicyclohexanol or CP-47,497 C8-homolog);
    18    (iii) 1-pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678);
    19    (iv) 1-butyl-3-(1-naphthoyl)indole (JWH-073);
    20    (v) 1-hexyl-3-(1-naphthoyl)indole (JWH-019);
    21    (vi) 1-{2-(4-morpholinyl)ethyl}-3-(1-naphthoyl)indole (JWH-200);
    22    (vii) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);
    23    (viii) 1-pentyl-3-{1-(4-methoxynaphthoyl)}indole (JWH-081);
    24    (ix) 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);
    25    (x) 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);
    26    (xi) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201);
    27    (xii) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694);
    28    (xiii) 1-pentyl-3-{(4-methoxy)-benzoyl}indole (SR-19 and RCS-4);
    29    (xiv)   1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole  (SR-18  and
    30  RCS-8); and
    31    (xv) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).
    32    § 2. This act shall take effect on the ninetieth day  after  it  shall
    33  have become a law.